Cargando…
The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
BACKGROUND: The treatment options for epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine kinase inhibitors (TKIs), stereotactic radiosurgery (SRS), whole‐brain radiotherapy, brain surgery, and antiangiogenesis therapy....
Autores principales: | Cheng, Wen‐Chien, Shen, Yi‐Cheng, Chien, Chun‐Ru, Liao, Wei‐Chih, Chen, Chia‐Hung, Hsia, Te‐Chun, Tu, Chih‐Yeh, Chen, Hung‐Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108041/ https://www.ncbi.nlm.nih.gov/pubmed/35394114 http://dx.doi.org/10.1111/1759-7714.14423 |
Ejemplares similares
-
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
por: Chen, Chieh-Lung, et al.
Publicado: (2022) -
Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
por: Cheng, Wen-Chien, et al.
Publicado: (2023) -
A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023) -
Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
por: Tu, Chih-Yen, et al.
Publicado: (2018) -
Endobronchial Ultrasound Changed the World of Lung Cancer Patients: A 11-Year Institutional Experience
por: Chen, Chia-Hung, et al.
Publicado: (2015)